for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Novo Nordisk Says Step 1 Trial Met Both Primary Endpoints

June 4 (Reuters) - Novo Nordisk A/S:

* REG- NOVO NORDISK REPORTS WEIGHT LOSS OF 14.9% (16.9% IF TAKEN AS INTENDED) IN STEP 1 TRIAL

* STEP 1 TRIAL MET BOTH PRIMARY ENDPOINTS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up